Promising Potential of CG Oncology’s Cretostimogene: A Buy Rating Justified by Superior Performance and Safety Profile

Analyst Sean Laaman from Morgan Stanley reiterated a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $55.00.

Sean Laaman has given his Buy rating due to a combination of factors that highlight the promising potential of CG Oncology’s cretostimogene. The final results from the Phase 3 BOND-003 trial presented at the American Urological Association meeting underscore cretostimogene’s superior performance in treating high-risk BCG-unresponsive non-muscle invasive bladder cancer. With a 33.7% complete response rate at 24 months, even without considering pending cases, cretostimogene outperforms existing approved therapies like Anktiva.
Moreover, the durability of cretostimogene’s response is notable, with a median duration of response of 27.9 months and a high percentage of patients remaining in complete response at 12 and 24 months. Additionally, the safety profile of cretostimogene is impressive, with no Grade 3 or higher treatment-related adverse events. These factors, combined with the competitive edge over other therapies such as TAR-200, which has a lower duration of response probability, reinforce the strong competitive profile of cretostimogene, justifying the Buy rating.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.